Lewis L. Lanier

This study modifies FcεR1γ with a 4-1BB co-stimulatory motif to enhance NK cell function against HLA-E+ cells, improving cytotoxicity in suppression-prone conditions.

This paper develops a genome engineering workflow for primary human NK cells using CRISPR/Cas9 and AAV6 to integrate and disrupt genes, enhancing anti-tumor function through targeted CAR expression.

This study shows that SYK negatively regulates NK cell signaling and that its deletion enhances CD19-CAR NK cell efficacy in cancer immunotherapy.

This study shows that NK cell receptor signaling and activation vary with cell cycle stages, with some proteins showing non-monotonic abundance changes.

The paper uses CITE-seq to analyze NK cell alterations in CAD patients, finding SPON2/IFNG ratio and adaptive NK cell signatures correlate with disease severity and inflammation.

This study shows PVRL2 suppresses anti-tumor immunity independently of PVRIG and TIGIT, with deletion reducing tumor growth more than PD-L1 loss.

This study quantifies how clonal stochasticity in NK cell responses to MCMV arises from proliferation and death dynamics of mature NK subsets.

The paper identifies TNFAIP3 variants in humans, Denisovans, and mice that modulate A20 phosphorylation, revealing a genetic mechanism for balancing immunity and microbial tolerance.